Novel Imidazo[4,5-c][1,2,6]thiadiazine 2,2-dioxides as antiproliferative trypanosoma cruzi drugs: Computational screening from neural network, synthesis and in vivo biological properties.

[1]  Maria Paola Costi,et al.  Current and Future Chemotherapy for Chagas Disease. , 2015, Current medicinal chemistry.

[2]  I. Molina,et al.  The use of posaconazole against Chagas disease , 2015, Current opinion in infectious diseases.

[3]  S. Wyllie,et al.  Nitro drugs for the treatment of trypanosomatid diseases: past, present, and future prospects , 2014, Trends in parasitology.

[4]  Fernando Salvador,et al.  Randomized trial of posaconazole and benznidazole for chronic Chagas' disease. , 2014, The New England journal of medicine.

[5]  S. Montgomery,et al.  Neglected Parasitic Infections in the United States: Chagas Disease , 2014, The American journal of tropical medicine and hygiene.

[6]  Y. Jackson,et al.  Chagas disease in Australia and New Zealand: risks and needs for public health interventions , 2014, Tropical medicine & international health : TM & IH.

[7]  M. Grijalva,et al.  Towards a Paradigm Shift in the Treatment of Chronic Chagas Disease , 2013, Antimicrobial Agents and Chemotherapy.

[8]  N. Campillo,et al.  Artificial neural networks based on CODES descriptors in pharmacology: identification of novel trypanocidal drugs against Chagas disease. , 2013, Current computer-aided drug design.

[9]  O. Ritter,et al.  Epidemiology of Chagas disease in Europe: many calculations, little knowledge , 2013, Clinical Research in Cardiology.

[10]  Miriam Navarro,et al.  Chagas Disease in Spain: Need for Further Public Health Measures , 2012, PLoS neglected tropical diseases.

[11]  F. Buckner,et al.  Recent Developments in Sterol 14-demethylase Inhibitors for Chagas Disease. , 2012, International journal for parasitology. Drugs and drug resistance.

[12]  N. Campillo,et al.  Amidines bearing benzofuroxan or benzimidazole 1,3-dioxide core scaffolds as Trypanosoma cruzi-inhibitors: structural basis for their interactions with cruzipain† , 2012 .

[13]  M. Segovia,et al.  Side effects of benznidazole treatment in a cohort of patients with Chagas disease in non-endemic country. , 2011, Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia.

[14]  B. Hall,et al.  Trypanocidal activity of nitroaromatic prodrugs: current treatments and future perspectives. , 2011, Current topics in medicinal chemistry.

[15]  A. López de Cerain,et al.  3-Trifluoromethylquinoxaline N,N'-dioxides as anti-trypanosomatid agents. Identification of optimal anti-T. cruzi agents and mechanism of action studies. , 2011, Journal of medicinal chemistry.

[16]  J. Silva,et al.  Current status of Chagas disease chemotherapy , 2011, Expert review of anti-infective therapy.

[17]  M. Segovia,et al.  Efectos secundarios del tratamiento con benznidazol en una cohorte de pacientes con enfermedad de Chagas en un país no endémico , 2011 .

[18]  N. Campillo,et al.  Development of second generation amidinohydrazones, thio- and semicarbazones as Trypanosoma cruzi-inhibitors bearing benzofuroxan and benzimidazole 1,3-dioxide core scaffolds , 2010 .

[19]  N. Campillo,et al.  Neural computational prediction of oral drug absorption based on CODES 2D descriptors. , 2010, European journal of medicinal chemistry.

[20]  W. Degrave,et al.  In vitro and in vivo experimental models for drug screening and development for Chagas disease. , 2010, Memorias do Instituto Oswaldo Cruz.

[21]  N. Campillo,et al.  Chagas disease: progress and new perspectives. , 2010, Current medicinal chemistry.

[22]  Christopher P Austin,et al.  Identification and optimization of inhibitors of Trypanosomal cysteine proteases: cruzain, rhodesain, and TbCatB. , 2010, Journal of medicinal chemistry.

[23]  A. Buschini,et al.  Genotoxicity Revaluation of Three Commercial Nitroheterocyclic Drugs: Nifurtimox, Benznidazole, and Metronidazole , 2009, Journal of parasitology research.

[24]  V. Duschak,et al.  Cruzipain, the major cysteine protease of Trypanosoma cruzi: a sulfated glycoprotein antigen as relevant candidate for vaccine development and drug target. A review. , 2009, Current medicinal chemistry.

[25]  M. G. Álvarez,et al.  Side effects of benznidazole as treatment in chronic Chagas disease: fears and realities , 2009, Expert review of anti-infective therapy.

[26]  D. Grana,et al.  Prognostic impact of Chagas disease in the United States. , 2009, American heart journal.

[27]  H. MarisaTorres,et al.  Guías clínicas de la enfermedad de Chagas 2006: Parte VI. Tratamiento antiparasitario de la enfermedad de Chagas , 2008 .

[28]  Nuria E. Campillo,et al.  Artificial Neural Networks in ADMET Modeling: Prediction of Blood–Brain Barrier Permeation , 2008 .

[29]  D. Horn,et al.  A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes , 2008, Proceedings of the National Academy of Sciences.

[30]  J. Castro,et al.  Toxic Side Effects of Drugs Used to Treat Chagas’ Disease (American Trypanosomiasis) , 2006, Human & experimental toxicology.

[31]  A. Gómez-Barrio,et al.  Development of resazurin microtiter assay for drug sensibility testing of Trypanosoma cruzi epimastigotes , 2006, Parasitology Research.

[32]  A. Osuna,et al.  Itraconazole or allopurinol in the treatment of chronic American trypanosomiasis: the results of clinical and parasitological examinations 11 years post-treatment , 2005, Annals of tropical medicine and parasitology.

[33]  J. Cazzulo.  Proteinases of Trypanosoma cruzi: Potential Targets for the Chemotherapy of Chagas Disease , 2005 .

[34]  A. Gómez-Barrio,et al.  A new pharmacological screening assay with Trypanosoma cruzi epimastigotes expressing β-galactosidase , 2005, Parasitology Research.

[35]  J. Cazzulo.  Proteinases of Trypanosoma cruzi: patential targets for the chemotherapy of Changas desease. , 2002, Current topics in medicinal chemistry.

[36]  J. Palmer,et al.  Cysteine protease inhibitors alter Golgi complex ultrastructure and function in Trypanosoma cruzi. , 1998, Journal of cell science.

[37]  F. Buckner,et al.  Efficient technique for screening drugs for activity against Trypanosoma cruzi using parasites expressing beta-galactosidase , 1996, Antimicrobial agents and chemotherapy.

[38]  V. Arán,et al.  Reactivity of malononitrile towards sulphamide and N-substituted sulphamides: synthesis and hydrolysis reactions of 3,5-diamino-1,2,6-thiadiazine 1,1-dioxides , 1988 .

[39]  C. Foces-Foces,et al.  A new route for the synthesis of 6-substituted imidazo[4,5-c]-1,2,6-thiadiazine 2,2-dioxides: NMR study and crystal structure of a complex with dimethylformamide , 1987 .

[40]  B. Ames,et al.  Revised methods for the Salmonella mutagenicity test. , 1983, Mutation research.

[41]  R. Tarone,et al.  Evaluating statistical analyses and reproducibility of microbial mutagenicity assays. , 1981, Mutation research.

[42]  W. Pfleiderer,et al.  Synthesis of purine-like ring systems derived from 1,2,6-thiadiazine 1,1-dioxide , 1976 .

[43]  Z. Brener.  Therapeutic activity and criterion of cure on mice experimentally infected with Trypanosoma cruzi. , 1962, Revista do Instituto de Medicina Tropical de Sao Paulo.